TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6789793

Group type: EXPERIMENTAL
Intervention: Lithium carbonate plus imipramine hydrochloride
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lithium carbonate plus placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 75
Study: 31175812

Group type: EXPERIMENTAL
Intervention: Infant weight and length SITAR parameters
Number of subjects: 902
Study: 30027612

Group type: EXPERIMENTAL
Intervention: Daily application of the antiaging cream (0.1% RAL, GGO, Pre-tocopheryl) for 8 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Three sequential glycolic acid (GA) peels (20%, 50%, and 70%) every 2-3 weeks
Number of subjects: 55
Study: 26936453

Group type: EXPERIMENTAL
Intervention: Chronic Pain Coding System (CPCS)
Number of subjects: 45
Study: 24335546

Group type: EXPERIMENTAL
Intervention: Arterial spin-labeling-MRI
Number of subjects: 13

Group type: COMPARATOR
Intervention: H2[15O]-PET
Number of subjects: 13
Study: 22471260

Group type: EXPERIMENTAL
Intervention: PLDLA implant arthroplasty
Number of subjects: 29

Group type: COMPARATOR
Intervention: Tendon interposition
Number of subjects: 29
Study: 20595906

Group type: EXPERIMENTAL
Intervention: Ritonavir 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17482177

Group type: EXPERIMENTAL
Intervention: Microdose GnRH agonist flare (ML)
Number of subjects: 534

Group type: COMPARATOR
Intervention: GnRH antagonist/letrozole (AL)
Number of subjects: 534
Study: 16126047

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (probiotics)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 11840407

Group type: EXPERIMENTAL
Intervention: Heparinized saline
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 49
Study: 12147332

Group type: EXPERIMENTAL
Intervention: Vanillin (pleasant odor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indole (unpleasant odor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right nostril stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left nostril stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensity judgment task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective judgment task
Number of subjects: 0
Study: 9524897

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACH) infusion
Number of subjects: 10
Study: 8121734

Group type: COMPARATOR
Intervention: Maternal cigarette smoking (10 or more cigarettes per day during pregnancy)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: No maternal cigarette smoking during pregnancy
Number of subjects: 400
Study: 2477909

Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 359252

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 50
Study: 30481999

Group type: EXPERIMENTAL
Intervention: Hemadsorption during CPB (Cytosorb®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no hemadsorption)
Number of subjects: 40
Study: 28029445

Group type: EXPERIMENTAL
Intervention: E10030 1.5 mg in combination with ranibizumab 0.5 mg
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: E10030 0.3 mg in combination with ranibizumab 0.5 mg
Number of subjects: 449

Group type: COMPARATOR
Intervention: Sham in combination with ranibizumab 0.5 mg (anti-VEGF monotherapy)
Number of subjects: 449
Study: 26856015

Group type: EXPERIMENTAL
Intervention: Experimental ultra‐low abrasivity desensitizing dentifrice (RDA ‐12)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Experimental low abrasivity desensitizing dentifrice (RDA ‐40)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Standard fluoride dentifrice (RDA ‐80)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Whitening dentifrice (RDA ‐142)
Number of subjects: 142
Study: 23896222

Group type: EXPERIMENTAL
Intervention: Don't Panic Online, an Internet‐based self‐help course for mild panic symptoms, based on cognitive behavioral principles and includes guidance by email.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 126
Study: 21843430

Group type: EXPERIMENTAL
Intervention: Free water intake (treatment group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no water intake)
Number of subjects: 54
Study: 19841765

Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composites (FRC) - Angelus Fibrex Ribbon, DentaPreg Splint, ever-Stick Ortho, Ribbond
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stainless steel wire - Quad Cat Wire (various application methods)
Number of subjects: 80
Study: 16636167

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (DDDR)
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Ventricular pacing (VVIR)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Cumulative percent ventricular pacing (Cum%VP) >80
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Cumulative percent ventricular pacing (Cum%VP) ≤80
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Cumulative percent ventricular pacing (Cum%VP) >40 or ≤80
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: QRS duration (QRSd)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Low baseline ejection fraction (EF)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Drugs for atrial fibrillation
Number of subjects: 2010
Study: 15658648

Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin pill (SBP)
Number of subjects: 111
Study: 11506052

Group type: EXPERIMENTAL
Intervention: systematic desensitization
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: humor desensitization
Number of subjects: 40

Group type: COMPARATOR
Intervention: untreated controls
Number of subjects: 40
Study: 9032192

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 mg twice daily for 2 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg daily for 2 weeks)
Number of subjects: 23
Study: 8498631

Group type: EXPERIMENTAL
Intervention: Random repeat recall method (14 random days during three 30-day waves)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Random repeat recall method (2 random days during each wave)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Summary measure from follow-up telephone interviews
Number of subjects: 142
Study: 2891867

Group type: EXPERIMENTAL
Intervention: Topical indometacin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beta-blocker and pilocarpine 2%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 60
Study: 31568378

Group type: EXPERIMENTAL
Intervention: Task-oriented functional training
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Wii Fit intervention
Number of subjects: 52
Study: 29320647

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 863

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study: 26758700

Group type: EXPERIMENTAL
Intervention: α‐MSH levels in obese children (1194±865 ng/mL)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: AgRP levels in obese children (828±417 ng/mL)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Correlation between plasma α‐MSH and AgRP levels
Number of subjects: 175
Study: 24313633

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg daily for 4 weeks (after initial 8 weeks of 50 mg)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Sertraline 50 mg daily for 8 weeks, continued for 4 weeks
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg daily for 8 weeks
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg daily for 4 weeks
Number of subjects: 218
Study: 22968625

Group type: EXPERIMENTAL
Intervention: Mineral supplementation (Se and Zn) for 60 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Healthy male subjects (control group)
Number of subjects: 144
Study: 20008828

Group type: EXPERIMENTAL
Intervention: supplemented very low-protein diet (sVLPD)
Number of subjects: 57

Group type: COMPARATOR
Intervention: dialysis
Number of subjects: 57
Study: 18069904

Group type: EXPERIMENTAL
Intervention: XP-828L 5 g/d for 56 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 15469666

Group type: EXPERIMENTAL
Intervention: Quetiapine (150 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 14551544

Group type: EXPERIMENTAL
Intervention: Endoscopic PCL reconstruction using looped autogenous hamstring tendons and an EndoButton.
Number of subjects: 51

Group type: COMPARATOR
Intervention: 2-incision PCL reconstruction using autogenous hamstring tendons.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Endoscopic PCL reconstruction
Number of subjects: 51
Study: 10648333

Group type: EXPERIMENTAL
Intervention: MST 20 mg 12 hourly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine sulfate 10 mg IM 6 hourly
Number of subjects: 0
Study: 9025796

Group type: EXPERIMENTAL
Intervention: Isotonic carbohydrate drink
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo drink (flavored water)
Number of subjects: 20
Study: 1496093

Group type: EXPERIMENTAL
Intervention: High combat with high social support
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High combat with low social support
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low combat with high social support
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low combat with low social support
Number of subjects: 80
Study: 6149758

Group type: EXPERIMENTAL
Intervention: +cyanidanol-3 (2 g daily, 500 mg qds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3780692

Group type: EXPERIMENTAL
Intervention: Spinal blockade with 0.5% bupivacaine (3 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural blockade with 0.5% bupivacaine (19 ml)
Number of subjects: 60
Study: 30045422

Group type: EXPERIMENTAL
Intervention: Oral Melissa officinalis (MO) 3 g/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 28679551

Group type: EXPERIMENTAL
Intervention: High glycemic load diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low glycemic load diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New Nordic Diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat and low-carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat and high-carbohydrate diet
Number of subjects: 0
Study: 25701171

Group type: EXPERIMENTAL
Intervention: Necitumumab plus pemetrexed and cisplatin
Number of subjects: 633

Group type: COMPARATOR
Intervention: Pemetrexed and cisplatin alone
Number of subjects: 633
Study: 23069274

Group type: EXPERIMENTAL
Intervention: Balanced Finnish‐Swedish bilinguals
Number of subjects: 2

Group type: COMPARATOR
Intervention: Monolingual native speakers of Finnish
Number of subjects: 2
Study: 20531162

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) intervention consisting of eight 90‐min sessions with 30 mins of each session devoted to PT, focusing on truncal and limb isodynamic strengthening and education.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) intervention
Number of subjects: 103
Study: 17713476

Group type: COMPARATOR
Intervention: Raltegravir (single-dose escalation study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raltegravir (multiple-dose escalation study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raltegravir (single-dose female study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raltegravir (general findings)
Number of subjects: 0
Study: 17149454

Group type: EXPERIMENTAL
Intervention: Yoga intervention (1 hour instructional session, followed by 4 weeks of daily home practice)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Yoga intervention (combined pre- and postintervention data)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Yoga intervention (subjective feedback)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wait list control group (before receiving yoga intervention)
Number of subjects: 25
Study: 12511185

Group type: EXPERIMENTAL
Intervention: Insulin-sensitive (IS) patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Insulin-resistant (IR) patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both groups (IS and IR)
Number of subjects: 61
Study: 9828796

Group type: EXPERIMENTAL
Intervention: 3D fast FLAIR sequence
Number of subjects: 10

Group type: COMPARATOR
Intervention: CSE (conventional spin echo)
Number of subjects: 10
Study: 7859960

Group type: EXPERIMENTAL
Intervention: Reversed group (received flumazenil before colonoscope withdrawal)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Not-reversed group (did not receive flumazenil before colonoscope withdrawal)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: No prior intravenous sedation (second phase)
Number of subjects: 81
Study: 2680158

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg once daily)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg three times daily)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (325 mg and 75 mg, respectively, three times daily)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (267 mg three times daily)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo (three times daily)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: All aspirin groups combined
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: All aspirin groups for grafts to vessels ≤ 2.0 mm
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: All aspirin groups for grafts to vessels > 2.0 mm
Number of subjects: 406
Study: 827773

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30282861

Group type: EXPERIMENTAL
Intervention: 10 g butter (B10)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 g butter (B20)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 g butter (B40)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g butter (control)
Number of subjects: 0
Study: 26440437

Group type: COMPARATOR
Intervention: IV tramadol (2 mg/kg, 3 mL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration with tramadol (2 mg/kg, 3 mL)
Number of subjects: 40
Study: 25241302

Group type: EXPERIMENTAL
Intervention: Antireflux microcatheter (ARM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coil embolization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 22388325

Group type: EXPERIMENTAL
Intervention: Mid-late systolic MR
Number of subjects: 201

Group type: COMPARATOR
Intervention: Holosystolic MR
Number of subjects: 201
Study: 20848729

Group type: EXPERIMENTAL
Intervention: Non-pharmacologic and pharmacologic options for ovulation induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 0
Study: 18544622

Group type: EXPERIMENTAL
Intervention: 1,500 IU daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10,500 IU once weekly
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 45,000 IU once every 28 days
Number of subjects: 48
Study: 15872124

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg plus metoclopramide 10 mg iv
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg iv
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 90
Study: 15385009

Group type: EXPERIMENTAL
Intervention: Early intravenous placement (30 seconds after loss of lid reflex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late intravenous placement (120 seconds after loss of lid reflex)
Number of subjects: 0
Study: 10073791

Group type: EXPERIMENTAL
Intervention: Niacin and etofibrate combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Niacin alone
Number of subjects: 0
Study: 7739926

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (200 U/kg i.v. three times a week during 4 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: no treatment (control group)
Number of subjects: 13
Study: 2197059

Group type: EXPERIMENTAL
Intervention: Prophylactic carotid endarterectomy for critical lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 0
Study: 394281

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltarol) 25 mg t.d.s. for 2 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Indomethacin 25 mg t.d.s. for 2 weeks
Number of subjects: 67
Study: 30041540

Group type: EXPERIMENTAL
Intervention: Early postoperative feeding (EPF) at 4 hours postoperatively
Number of subjects: 140

Group type: COMPARATOR
Intervention: Late postoperative feeding (LPF) at 8 hours or more postoperatively
Number of subjects: 140
Study: 30107043

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg, twice daily for 52 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo, twice daily for 52 weeks
Number of subjects: 102
Study: 27399104

Group type: EXPERIMENTAL
Intervention: Free-breathing CCTA (group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Breath-holding CCTA (group A)
Number of subjects: 80
Study: 25231565

Group type: EXPERIMENTAL
Intervention: Active bioresonance therapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 22614031

Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEB-DOX)
Number of subjects: 173
Study: 19874636

Group type: EXPERIMENTAL
Intervention: High-almond diet (20% isoenergetic replacement of control diet with almonds)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-almond diet (10% isoenergetic replacement of control diet with almonds)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet (no nuts, < 30% energy from fat)
Number of subjects: 25
Study: 17324006

Group type: EXPERIMENTAL
Intervention: orBec® (beclometasone)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 16203880

Group type: EXPERIMENTAL
Intervention: Total shoulder arthroplasty
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 42
Study: 11990662

Group type: EXPERIMENTAL
Intervention: Transvenous biventricular defibrillation using a left venous access defibrillation electrode (LVA lead)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard right ventricular defibrillation system
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transvenous biventricular defibrillation
Number of subjects: 24
Study: 10380428

Group type: EXPERIMENTAL
Intervention: Antifungal drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: C. albicans antigen
Number of subjects: 0
Study: 8671157

Group type: EXPERIMENTAL
Intervention: Follegon
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metrodin
Number of subjects: 16
Study: 1816280

Group type: EXPERIMENTAL
Intervention: prazepam + ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: prazepam alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo + ethanol
Number of subjects: 12
Study: 6751374

Group type: EXPERIMENTAL
Intervention: Oral beta-carotene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical benzimidazole sunscreen cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 0
Study: 31481683

Group type: EXPERIMENTAL
Intervention: Seltorexant (JNJ-42847922/MIN-202)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Diphenhydramine
Number of subjects: 47
Study: 28126898

Group type: EXPERIMENTAL
Intervention: Atosiban (6.75 mg)
Number of subjects: 830

Group type: COMPARATOR
Intervention: Fenoterol (40 μg)
Number of subjects: 830
Study: 26820158

Group type: EXPERIMENTAL
Intervention: Vitamin E, C, A, and N-acetylcysteine daily (treatment group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 29
Study: 24877167

Group type: EXPERIMENTAL
Intervention: MuGard
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham control rinse (SC)
Number of subjects: 120
Study: 20624657

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 12 mg
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6 mg
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 3 mg
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study: 20334503

Group type: EXPERIMENTAL
Intervention: Alternative GOSE rating system coupled with central quality control (Group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Alternative GOSE rating system alone (Group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional structured interviews (Group 3)
Number of subjects: 45
Study: 17265397

Group type: EXPERIMENTAL
Intervention: Engineered sharps injury prevention device (ESIPD) - intravenous (IV) catheter stylet with a safety-engineered feature (retractable protection shield)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suture needles (no protective devices present)
Number of subjects: 0
Study: 16344034

Group type: EXPERIMENTAL
Intervention: BROM device for measuring side bending
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: BROM device for measuring lumbar forward flexion and pelvic inclination
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: BROM device for measuring lumbar extension and rotation
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: BROM device for measuring all lumbar motions and pelvic inclination
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Palpation consistency
Number of subjects: 91
Study: 12413985

Group type: EXPERIMENTAL
Intervention: Tibolone, 2.5 mg/d for 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 30
Study: 10220653

Group type: EXPERIMENTAL
Intervention: Neo-Temp luting agent
Number of subjects: 10

Group type: COMPARATOR
Intervention: Temp Bond luting agent
Number of subjects: 10

Group type: COMPARATOR
Intervention: Provilink luting agent
Number of subjects: 10